Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Moscow announces another offset contract of 8.2 billion rubles for drugs supply
Applications for the contract will be accepted until February 20, with results announced on February 27.
Moscow: The Moscow Department of Competition Policy announced a competitive selection procedure with an initial price of 8.2 billion rubles for the conclusion of offset contracts for medicines supply with investment commitments for the establishment or modernization of production in the city.
Applications for the contract will be accepted until February 20, with results announced on February 27. The contractor must invest at least 800 million rubles in the organisation of the production of 57 medicines with 43 INNs, according to the terms of the competitive selection procedure. It is proposed to establish production of 15 medicines that are not on the list of Vital and Essential Drugs. The delivery dates range from January 2026 to February 2030.
Moscow proposes to manufacture a wide range of drugs, including antitumor, hormonal, and anti-Parkinson drugs, analgesics, vitamins A and D and combinations, and ophthalmic products. Botulinum toxin type A hemagglutinin complex and botulinum toxin type A are also on the list.
According to the Analytical Bureau of GxP News, seven registered and the same number of unregistered type A botulinum toxins were in circulation on the Russian aesthetic medicine market in 2022. . According to GxP News, the market volume is 2.6 million treatments per year. The neutral scenario predicts that the cosmetology botulinum toxin market will remain stable in the coming years, with approximately 2.5 million treatments per year.
Moscow has already signed offset contracts with ZAO Biocad and AO R-Pharm in the pharmaceutical sector. The contracts call for the production of oncological, cardiological, endocrinological, and immunomodulatory drugs to be centralised in the city. The two offset contracts total 8.8 billion rubles in investment, with a delivery volume of 32.4 billion rubles. Biocad already provides medicines to the city, and R-Pharm plans to begin production in early 2023.